시장보고서
상품코드
1119565

세계의 엑소좀 시장 : 시장 규모, 예측, 임상시험, 동향(2022년)

The Global Exosome Market - Market Size, Forecast, Trials and Trends, 2022

발행일: | 리서치사: BioInformant Worldwide LLC | 페이지 정보: 영문 312 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

엑소좀 기술은 최근 빠르게 발전하고 있으며, 액체생검, 정밀의료, 재생의료 등 분야로의 통합에 의한 시장의 상당한 성장이 예측됩니다.

세계의 엑소좀(Exosome) 시장에 대해 조사 분석했으며, 시장 규모, 임상시험 상황, 경쟁사 개요 등을 제공합니다.

목차

제1장 보고서 개요

제2장 엑소좀 : 개요

  • 엑소좀 구조
  • 엑소좀 분류
  • 인공 엑소좀의 바이오메디컬 응용
  • 엑소좀 기능
  • 엑소좀 치료와 세포 치료의 차이
  • 조사용 엑소좀 원료
  • 바이오마커로서의 엑소좀 활용
  • 세포 치료로부터 엑소좀 치료로의 이동

제3장 엑소좀 엔지니어링 : 새로운 플랫폼

  • 내면 변성
  • 표면 변성
  • 변성 방법 비교
  • 디자이너 엑소좀의 임상 응용
  • 개변 엑소좀 기반 치료법을 개발하고 있는 기업

제4장 재생의료의 MSC 유래 엑소좀

  • 심혈관질환
  • 신장병
  • 간질환
  • 창상 치유
  • 재생의료를 위한 MSC 엑소좀 기반 임상시험

제5장 엑소좀 연구

  • 질환 유래 엑소좀을 저해하기 위한 연구
  • 엑소좀 연구의 일반적인 분리 방법
  • 엑소좀 연구의 엑소좀 품질 관리(QC)
  • 엑소좀 연구에서 사용되는 바이오이미징 모달리티
  • 엑소좀 연구에서 사용되는 라벨링 방법
  • 엑소좀 연구의 엑소좀 용량 결정
  • 엑소좀 투여 경로
  • 연구의 엑소좀 특성화

제6장 시판 엑소좀 연구 툴

  • 엑소좀 캡처/정량화 키트
  • 엑소좀 표준
  • 엑소좀 포획용 면역플레이트
  • 엑소좀 분리용 면역비즈
  • 엑소좀 마커 항체

제7장 엑소좀의 과학 출판물

  • 세계의 출판물 동향
  • 엑소좀 연구 출판물의 미래

제8장 엑소좀 특허 전망

  • 현재 엑소좀 특허 상황 개요
  • 엑소좀 특허 주요 양수인
  • 엑소좀 특허/특허 출원 : 지역별
  • 엑소좀 특허/특허 출원의 법적 지위
  • 담당자 카테고리

제9장 엑소좀 : 임상시험 상황

  • 임상시험에서 사용되는 엑소좀 원료
  • 항종양 항원을 이용한 연구
  • 암에 대한 세포 독성약을 사용한 연구
  • 진행중인 엑소좀 기반 임상시험 모집 상황
  • 연구 설계
  • 연구 단계
  • 자금 조달 종류
  • 엑소좀 임상시험 : 지역별
  • MSC 유래 엑소좀을 포함한 임상시험
  • 약물 부하 엑소좀을 포함한 임상시험 사례

제10장 엑소좀 제조 현황

  • 세포배양으로부터의 엑소좀 생산
  • 제작 포맷
  • 엑소좀 관련 서비스를 제공하는 기업

제11장 엑소좀 분리 어프로치

  • 초원심 분리
  • 한외여과 및 순차적 한외여과
  • 사이즈 배제 크로마토그래피
  • 폴리머 침전
  • 면역친화성 캡처
  • 마이크로플루이딕스 기반 기술
  • 시판 엑소좀 분리 키트
  • 각 엑소좀 분리 방법 요약
  • 엑소좀 특성화
  • 엑소좀 이미징용 마이크로스코피와 나노스코피
  • 이미징용 직접 사후 격리 라벨링
  • 유전자·단백질 바이오마커의 엑소좀 분석을 위한 어프로치
  • 엑소좀 분석을 위한 새로운 광학 기술
  • 새로운 전기화학적·전기기계적 어프로치

제12장 엑소좀 진단으로의 응용

  • 진단 바이오마커로서의 엑소좀 단백질
  • 바이오마커로서의 엑소좀 핵산
  • 암 바이오마커로서의 엑소좀 논코딩 RNA
  • 임신 장애의 엑소좀 바이오마커
  • 엑소좀 바이오마커와 면역 거부반응 조기 진단
  • 엑소좀 기반 진단에 관한 PubMed 기사수
  • 엑소좀 기반 진단을 포함한 임상시험

제13장 엑소좀 치료로의 응용

  • 치료제로서 엑소좀의 이점
  • 치료용 엑소좀 플랫폼
  • 엑소좀의 캡슐화된 약물
  • 부하 엑소좀 치료를 포함한 전임상 연구
  • 엑소좀 치료를 포함한 임상시험

제14장 백신 개발의 엑소좀 응용

  • 동물 모델의 엑소좀 기반 면역요법
  • 백신 개발의 엑소좀을 포함한 진행중인 임상시험

제15장 엑소좀 업계 현황

  • 세포 치료에서 엑소좀 치료로의 이동
  • 엑소좀 임상 응용
  • 엑소좀 기반 진단에 초점을 맞춘 임상시험
  • 엑소좀 치료로의 응용
  • 엑소좀 치료제 후보에 의해 치료 가능한 질환
  • 엑소좀 기반 백신 개발
  • 엑소좀 기반 임상시험 현황
  • 엑소좀 연구에 대한 NIH 자금 제공
  • 엑소좀 공간의 거래와 자금 조달
  • 엑소좀 부문의 현재 업계 리더
  • 엑소좀 기업의 4개 카테고리
  • 현재 엑소좀 기술 : 영리 기업별

제16장 엑소좀 시장 분석

  • 엑소좀 치료 시장
  • 엑소좀 진단 시장
  • 엑소좀 연구 제품 시장

제17장 엑소좀 시장 경쟁사 개요

  • 101 Bio
  • Abbexa, Ltd.
  • Abnova
  • Adipomics, Inc.
  • Aegle Therapeutics
  • AgeX Therapeutics
  • Aethlon Medical, Inc.
  • Ambiotech
  • AMS Biotechnology, Ltd.(AMSBIO)
  • Anjarium Biosciences
  • Antibodies-Online GmbH
  • Aposcience AG
  • Aruna Bio
  • Avalon GloboCare Corp.
  • Aviva Systems Biology
  • Azymus Therapeutics
  • Beckman Coulter Life Sciences
  • BioCat GmbH
  • BioFluidica
  • Biological Dynamics, Inc.
  • Biorbyt, Ltd.
  • BioRegenerative Sciences, Inc.
  • Bio-Techne
  • BioVision, Inc.
  • BrainStorm Cell Therapeutics
  • BreStem Therapeutics, Inc.
  • Capricor Therapeutics
  • Carmine Therapeutics
  • CD Bioparticles
  • Cellarcus Biosciences, Inc.
  • Cell Care Therapeutics
  • Cell Factory BVBA/Esperite NV
  • Cell Guidance Systems, Ltd.
  • Ciola
  • CK-Exogene
  • Clara Biotech
  • Codiak Biosciences
  • Coya Therapeutics, Inc.
  • Craif, Inc.
  • Creative Bioarray
  • CreativeBiostructure
  • Creative Biolabs
  • Creative Medical Technology Holdings
  • Creative Proteomics
  • Curexsys GmbH
  • CUSABIO TECHNOLOGY LLC
  • Diadem Biotherapeutics
  • Direct Bio
  • DLdevelop
  • Entelexo Biotherapeutics
  • EverZom
  • Evomic Science LLC
  • Evora Biosciences SAS
  • Evox Therapeutics, Ltd.
  • ExBiome BV
  • Exrkine Corp.
  • ExoCan Healthcare Technologies, Pvt. Ltd.
  • ExoCoBio, Co., Ltd.
  • Exogenus Therapeutics
  • ExoPERT
  • ExoPharm
  • ExosomeDx(biotechne)
  • ExosomePlus
  • Exosome Sciences
  • Exosomics S.p.A
  • ExoVectory
  • Florica Therapeutics
  • GenWay Biotech, Inc.
  • HansaBioMed Lifesiences, Ltd.
  • ILIAS Biologics, Inc.
  • Innocan Pharma
  • Innovex Therapeutics, S.L
  • INOVIQ, Ltd.
  • Invent Biotechnologies, Inc.
  • Izon Science, Ltd.
  • Kimera Labs, Inc.
  • Leading Biology, Inc.
  • LifeSpan Biosciences, Inc.
  • Lonza Group, Ltd.
  • Mantra Bio
  • MDimune, Inc.
  • Miltenyi Biotech B.V. and Co., KG
  • miR Scientific
  • Mursla, Ltd.
  • MyBioSource, Inc.
  • NanoSomics, Inc.
  • NanoView Biosciences
  • NeurExo Sciences
  • NeuroDex, Inc.
  • NurExone Biologic Ltd
  • New England Peptide, Inc.
  • Norgen Biotek Corp.
  • Novus Biologicals, LLC
  • nRix Dx, Inc.
  • Oasis Diagnostics Corporation
  • OmniSpirant, Ltd.
  • Organicell
  • OriGene Technologies, Inc.
  • Paracrine Therapeutics, Pvt. Ltd.
  • QIAGEN
  • ReNeuron
  • RION
  • RoosterBio, Inc.
  • Rosetta Exosome
  • System Biosciences, LLC
  • Tavec Pharma
  • Theoria Science, Inc.
  • Thermo Fisher Scientific
  • TransGen Biotech, Co., Ltd.
  • TriArm Therapeutics, Co., Ltd.
  • United Therapeutics Corp.
  • Versatope Therapeutics
  • Vesigen Therapeutics, Inc.
  • VivaZome Therapeutics, Pvt. Ltd.
  • Xollent Biotech
  • XOStem, Inc.
  • YMAIR Genomics, LLC

그림 색인

표 색인

KSM 22.09.08

EXECUTIVE SUMMARY

Exosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.

Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells.

The cargo contained within exosomes can offer prognostic information for range of diseases-including cardiovascular, renal, neurodegenerative, and metabolic diseases-as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.

Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient's response to a specific course of treatment.

Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient's exosomes can be isolated, modified with the appropriate siRNA or protein, and then injected back into the patient for treatment. Many approaches are being researched for creating drug-loaded exosomes. Furthermore, exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.

For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. Today, there are an astounding 18,000+ articles published about exosomes on PubMed.gov, of which an astounding three-quarters (74%) were released in the past five years.

When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and China comes in second place. When the term "exosome" is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author. When the term "extracellular vesicles" is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Professor Giovanni Camussi.

To date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. Within the past 5 years, there has been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.

Globally, there are at least 204 clinical trials focusing on exosome-related studies. Of these, 114 trials are evaluating exosome-based therapeutics and 74 trials are testing exosome-based diagnostic tests. Currently, 93 of the exosome trials (45%) are observational studies and 111 of them (55%) are interventional studies. The exosome industry has also achieved two landmark approvals of FDA-approved diagnostic tests: Bio-Techne's ExoDx Prostate IntelliScore Test for prostate cancer and Guardant's 360 CDx test for non-small cell lung cancer.

Exosome Market Forces

To characterize the rapidly expanding exosome market, BioInformant has released a 274-page global market report that explores growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials.

It highlights information about exosome industry partnerships, merger and acquisition (M&A) activity, and financing events. It features company profiles for 107 global competitors from across the exosome marketplace. Importantly, it presents market size determinations by market segment with forecasts through 2028.

Today the exosome industry is witnessing:

  • A surging number of scientific papers investigating exosomes and their applications
  • Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics
  • Swelling appetite among investors for exosome technology
  • An increasingly competitive IP environment
  • A diverse range of co-development partnerships
  • Proliferating numbers of exosome competitors in all major life science markets worldwide

This 274-page global strategic report about the exosome industry reveals:

  • 1. The pipeline for exosome therapeutics in 2021
  • 2. Clinical trial activity by type, region, phase, and sponsor
  • 3. Exosome industry events, including M&A activity, financing events, and IPOs
  • 4. Strategic partnerships and co-development agreements
  • 5. Competitors composing the global marketplace, including core technologies and products under development
  • 6. Market size determinations by market segment, with forecasts through 2028
  • 7. Exosome industry trends, competitive opportunities, and future directions for the global market
  • 8. And so much more

Claim this global strategic report to:

  • 1. Get educated about the rapidly evolving exosome market
  • 2. Identify opportunities for exosome product development
  • 3. Reveal the identities of all known competitors developing exosome research products, diagnostics, therapeutics, and manufacturing technologies
  • 4. Purse external funding from investors
  • 5. Make smarter decisions, faster

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Target Demographic
  • 1.3. Report Sources
  • 1.4. Purpose of the Report
  • 1.5. Executive Summary
  • 1.6. Introduction

2. EXOSOMES: AN OVERVIEW

  • 2.1. Structure of an Exosome
    • 2.1.1. Molecular Contents of Exosomes
      • 2.1.1.1. Proteins in Exosomes
      • 2.1.1.2. Lipid Contents of Exosomes
      • 2.1.1.3. Nucleic Acids in Exosomes
    • 2.1.2. Components of Membrane and Lumen of Exosomes
  • 2.2. Classification of Exosomes
    • 2.2.1. Natural Exosomes
      • 2.2.1.1. Isolation of Natural Exosomes
    • 2.2.2. Modified Exosomes
      • 2.2.2.1. Types of Therapeutic Cargo used in Exosome Modifications
    • 2.2.3. Synthetic Exosomes
  • 2.3. Biomedical Applications of Engineered Exosomes
  • 2.4. Functions of Exosomes
    • 2.4.1. Pivotal Role of Exosomes
    • 2.4.2. Adaptability to Engineering
  • 2.5. Differences between Exosome Therapy and Cell Therapy
  • 2.6. Sources of Exosomes for Research
  • 2.7. Leveraging Exosomes as Biomarkers
  • 2.8. The Shift from Cell Therapy to Exosome Therapy

3. EXOSOME ENGINEERING: THE NEW PLATFORM

  • 3.1. Interior Modification
    • 3.1.1. Pre-Isolation Interior Modification Methods
      • 3.1.1.1. Incubation
      • 3.1.1.2. Gene Editing
    • 3.1.2. Post-Isolation Interior Modification Methods
  • 3.2. Surface Modifications
    • 3.2.1. Surface Modification through Parent Cells
    • 3.2.2. Direct Surface Modification
    • 3.2.3. Loaded and Displayed Molecules in Direct Exosome Engineering
  • 3.3. Comparison of Modification Methods
  • 3.4. Clinical Applications of Designer Exosomes
    • 3.4.1. Targeted Designer Exosomes
    • 3.4.2. Anti-Cancer Designer Exosomes
    • 3.4.3. Regenerative Designer Exosomes
  • 3.5. Companies Developing Engineered Exosome-Based Therapeutics

4. MSC-DERIVED EXOSOMES IN REGENERATIVE MEDICINE

  • 4.1. Cardiovascular Diseases
  • 4.2. Kidney Diseases
  • 4.3. Liver Diseases
  • 4.4. Wound Healing
  • 4.5. MSC Exosome-Based Clinical Trials for Regenerative Medicines

5. EXOSOME RESEARCH

  • 5.1. Research to Inhibit Disease-Derived Exosomes
    • 5.1.1. Research to use Exosomes as Therapeutic Platforms
    • 5.1.2. Research to use Exosomes as Carriers of Genes in Gene Therapy
    • 5.1.3. Research to use Exosomes as Drug Delivery Vehicles
    • 5.1.4. Research to Develop Technologies for Exosome Isolation
  • 5.2. Common Isolation Methods in Exosome Research
  • 5.3. Quality Control (QC) of Exosomes in Exosome Research
  • 5.4. Bioimaging Modalities used in Exosome Research
  • 5.5. Labeling Methods used in Exosome Research
    • 5.5.1. Fluorescent Dyes used in Labeling Exosomes
    • 5.5.2. Common Methods to Remove Unlabelled Probes
  • 5.6. Determination of Exosome Dose in Exosome Studies
  • 5.7. Routes of Exosome Administration
  • 5.8. Characterization of Exosomes in Research

6. COMMERCIALLY AVAILABLE EXOSOME RESEARCH TOOLS

  • 6.1. Exosome Capture/Quantification Kits
    • 6.1.1. Exosome-associated RNA Isolation Kits
  • 6.2. Exosome Standards
  • 6.3. Immunoplates for Capturing Exosomes
  • 6.4. Immunobeads for Exosome Isolation
  • 6.5. Exosome Marker Antibodies

7. SCIENTIFIC PUBLICATIONS IN EXOSOMES

  • 7.1. Trends in Global Publications
    • 7.1.1. Scientific Publications on Exosome DNA as Diagnostics
    • 7.1.2. Scientific Publications on Exosome RNA as Diagnostics
    • 7.1.3. Scientific Publications on Exosome Proteins as Diagnostics
    • 7.1.4. Scientific Publications on Exosomes Derived from Stem Cells
    • 7.1.5. Scientific Publications on Exosome-based Diagnostics
    • 7.1.6. Scientific Publications on Exosome-based Therapeutics
    • 7.1.7. Scientific Publications on Exosomes for Cancer Diagnosis
    • 7.1.8. Scientific Publications on Exosomes for Pregnancy Disorders Diagnosis
  • 7.2. Future in Exosome Research Publications

8. EXOSOME PATENT LANDSCAPE

  • 8.1. A Brief Overview of Current Exosome Patent Landscape
    • 8.1.1. Patents/Patent Applications Relevant to Exosome-Sources
    • 8.1.2. Patents/Applications Related to Exosomes-Isolation/Preparation
    • 8.1.3. Patents/Applications Related to Type of Cargo
    • 8.1.4. Patents/Applications Related to Cargo Loading Methods
    • 8.1.5. Patents/Applications Related to Therapy Area
  • 8.2. Leading Assignees of Exosome Patents
    • 8.2.1. Types of Patented Isolation/Preparation Technologies by Assignees
    • 8.2.2. Types of Cargos Employed by Assignees
    • 8.2.3. Cargo Loading Methods by Assignees
    • 8.2.4. Therapy Areas by Assignees
  • 8.3. Exosome Patent/Patent Applications by Geography
  • 8.4. Legal Status of Exosome Patent/Patent Applications
  • 8.5. Assignee Categories

9. EXOSOMES: CLINICAL TRIAL LANDSCAPE

  • 9.1. Sources of Exosomes used in Clinical Trials
  • 9.2. Studies using Anti-Tumor Antigens
  • 9.3. Studies using Cytotoxic Drugs against Cancer
  • 9.4. Recruitment Status of Ongoing Exosome-based Clinical Trials
  • 9.5. Study Designs
  • 9.6. Study Phases
  • 9.7. Funding Types
  • 9.8. Exosome Clinical Trials by Geography
  • 9.9. Clinical Trials Involving MSC-Derived Exosomes
  • 9.10. Examples of Clinical Trials involving Drug-Loaded Exosomes

10. CURRENT STATUS OF EXOSOME MANUFACTURING

  • 10.1. Production of Exosomes from Cell Cultures
  • 10.2. Production Formats
    • 10.2.1. Large Scale Production
      • 10.2.1.1. Upstream Cell Line Production
      • 10.2.1.2. Downstream Exosome Purification Methods
  • 10.3. Companies Offering Exosome-Related Services

11. EXOSOME ISOLATION APPROACHES

  • 11.1. Differential Ultracentrifugation
    • 11.1.1. Gradient Density Ultracentrifugation
  • 11.2. Ultrafiltration & Sequential Ultrafiltration
  • 11.3. Size-exclusion Chromatography
  • 11.4. Polymer Precipitation
  • 11.5. Immunoaffinity Capture
  • 11.6. Microfluidics-Based Techniques
    • 11.6.1. Active and Passive Methods of Microfluidics-based Platforms
  • 11.7. Commercially Available Exosome Isolation Kits
    • 11.7.1. Comparison of Currently used Exosome Isolation Techniques
    • 11.7.2. Quality of Exosomes Isolated by Different Methods
  • 11.8. Summary of Different Exosome Isolation Methods
  • 11.9. Characterization of Exosomes
    • 11.9.1. Size and Shape
    • 11.9.2. Molecular Profiling
    • 11.9.3. Proteomics and Lipidomics
    • 11.9.4. Genomics
  • 11.10. Microscopy and Nanoscopy for Exosome Imaging
  • 11.11. Direct Post-Isolation Labeling for Imaging
  • 11.12. Approaches for Exosome Analysis for Gene and Protein Biomarkers
  • 11.13. Emerging Optical Technologies for Exosome Analysis
  • 11.14. Emerging Electrochemical and Electromechanical Approaches

12. DIAGNOSTIC APPLICATIONS OF EXOSOMES

  • 12.1.1. Exosomal Proteins as Diagnostic Biomarkers
  • 11.1.2. Exosomal Nucleic Acids as Biomarkers
  • 12.1.3. Non-Coding RNAs in Exosomes as Biomarkers in Cancers
    • 12.1.3.1. Exosomes from other Biofluids as Biomarkers for Cancer
  • 12.2. Exosome Biomarkers in Pregnancy Disorders
  • 12.3. Exosome Biomarkers and Early Diagnosis of Immunologic Rejection
  • 12.4. Number of PubMed Articles on Exosome-Based Diagnosis
  • 12.5. Clinical Trials involving Exosome-based Diagnostics

13. THERAPEUTC APPLICATIONS OF EXOSOMES

  • 13.1. Advantages of Exosomes as Therapeutics
  • 13.2. Therapeutic Exosome Platforms
    • 13.2.1. Naïve Exosome Therapeutics
    • 13.2.2. Engineered Exosome Therapeutics
      • 13.2.2.1. Passive Cargo Loading
      • 13.2.2.2. Active Cargo Loading
  • 13.3. Drugs Encapsulated in Exosomes
  • 13.4. Preclinical Studies involving Loaded Exosome Therapeutics
  • 13.5. Clinical Trials involving Exosome Therapeutics

14. APPLICATION OF EXOSOMES IN VACCINE DEVELOPMENT

  • 14.1. Exosome-Based Immunotherapy in Animal Models
  • 14.2. Ongoing Clinical Trials Involving Exosomes in Developing Vaccines

15. CURRENT STATUS OF EXOSOME INDUSTRY

  • 15.1. The Shift from Cell Therapy to Exosome Therapy
  • 15.2. Clinical Applications of Exosomes
    • 15.2.1. Diagnostic Applications
    • 5.2.2. Approved Exosome Diagnostics
      • 15.2.2.1. ExoDx Prostate IntelliScore (EPI) Test
      • 15.2.2.2. Guardant360 CDx
  • 15.3. Clinical Trials Focusing on Exosome-Based Diagnostics
  • 15.4. Therapeutic Applications of Exosomes
    • 15.4.1. Promising Exosome-Based Therapeutic Candidates
      • 15.4.1.1. AB 126
      • 15.4.1.2. AGLE-102
      • 15.4.1.3. AVA-201
      • 15.4.1.4. AVA-202
      • 15.4.1.5. AZ001
      • 15.4.1.6. CAP-2003
      • 15.4.1.7. exoIL-12
      • 15.4.1.8. ExoPr0
      • 15.4.1.9. exoSTING
      • 15.4.1.10. Plexaris
      • 15.4.1.11. UNEX-42
      • 15.4.1.12. Unexisome
  • 15.5. Addreseable Diseases by Exosome Therapeutic Candidates
  • 15.6. Exosome-Based Vaccine Development
  • 15.7. Current Status of Exosome-Based Clinical Trials
  • 15.8. NIH Funding for Exosome Research
  • 15.9. Deals and Fund Raising in Exosome Space
    • 15.9.1. Partnership Deals within Exosome Space
      • 15.9.1.1. Exopharm and Astellas
      • 15.9.1.2. Univercells Technologies and RoosterBio
      • 15.9.1.3. AgeX Therapeutics and UCI
      • 15.9.1.4. VivaZome and La Trobe University
      • 15.9.1.5. Evotec SE and Curexsys GmbH
      • 15.9.1.6. Bio-Techne and QIAGEN
      • 15.9.1.7. InnoCan Pharma and Recipharms
      • 15.9.1.8. Sarepta Therapeutics and Codiak Biosciences
      • 15.9.1.9. Navigo Proteins and MDimune
      • 15.9.1.10. Evox Therapeutics and Takeda
      • 15.9.1.11. Jazz Pharmaceuticals and Codiak Biosciences
      • 15.9.1.12. PureTech Health and Roche
      • 15.9.1.13. Exosome Diagnostics and Intezyne
      • 15.9.1.14. Evox Therapeutics and Boehringer Ingelheim
    • 15.9.2. Acquisition Deals
      • 15.9.2.1. Lonza's Acquisition of Exosomics
      • 15.9.2.2. Lonza and Codiak Biosciences
      • 15.9.2.3. Bio-Techne and Exosome Diagnostics
      • 15.9.2.4. Lonza and HansaBioMed
    • 15.9.3. Licensing Deals
      • 15.9.3.1. Evox Therapeutics and Eli Lilly
      • 15.9.3.2. VivaZome Therapeutics and University of Adelaide
      • 15.9.3.3. CEVEC and Evox Therapeutics
      • 15.9.3.4. Orgenesis and Excella Bio
    • 15.9.4. Fund Raising in Exosome Space
      • 15.9.4.1. Series C Financing Round by Evox Therapeutics
      • 15.9.4.2. Series B Financing Round for ILIAS Biologics
      • 15.9.4.3. Initial Public Offering (IPO) by Codiak Biosciences
      • 15.9.4.4. Series C Funding for ExoCoBio
      • 15.9.4.5. Common Stock Financing by ArunA Bio
      • 15.9.4.6. Early-Stage Award for Evox Therapeutics
      • 15.9.4.7. Series A Funding for ExoCoBio
      • 15.9.4.8. NIH Grant for Capricor
  • 15.10. Current Industry Leaders in Exosome Sector
    • 15.10.1. ArunA Biomedical
    • 15.10.2. Capricor Therapeutics
    • 15.10.3. Codiak Biosciences
    • 15.10.4. Evox Therapeutics
    • 15.10.5. Exosome Diagnostics, Inc (Bio-Techne)
    • 15.10.6. Exocyte Therapeutics
    • 15.10.7. Kimera Labs
    • 15.10.8. NanoSomiX
  • 15.11. The Four Categories of Exosome Companies
  • 15.12. Current Exosome Technologies by Commercial Companies
    • 15.12.1. Brief Descriptions of Major Exosome Technologies and Companies
      • 15.12.1.1. AGLE-102 from Aegle Therapeutics
      • 15.12.1.2. CDC Exosomes from Capricor Therapeutics
      • 15.12.1.3. engEX Platform from Codiak Biosciences
      • 15.12.1.4. DeliverEX from Evox Therapeutics
      • 15.12.1.5. Exo-101 from Exogenus Therapeutics
      • 15.12.1.6. Hybridozome from Anjarium Biosciences
      • 15.12.1.7. Neuronal Exosomes from Aruna Bio
      • 15.12.1.8. ExoPro from ReNeuron
      • 15.12.1.9. Plexaris from Exopharm Pty., Ltd.
      • 15.12.1.10. ExoSCRT from ExoCoBio

16. EXOSOME MARKET ANALYSIS

  • 16.1. Market for Exosome Therapeutics
  • 16.2. The Market for Exosome Diagnostics
  • 16.3. Market for Exosome Research Products
    • 16.3.1. Market Shares for Exosome Isolation Tools
    • 16.3.2. Percent Utilization of Research Tools used on Captured Exosomes

17. PROFILES OF EXOSOME MARKET COMPETITORS

  • 17.1. 101 Bio
    • 17.1.1. Exosome Services
  • 17.2. Abbexa, Ltd.
  • 17.3. Abnova
  • 17.4. Adipomics, Inc.
  • 17.5. Aegle Therapeutics
    • 17.5.1. Extracellular Vesicle Therapy
  • 17.6. AgeX Therapeutics
    • 17.6.1. PureStem Technology
    • 17.6.2. Induced Tissue Regeneration
    • 17.6.3. UniverCyte
    • 17.6.4. HyStem Delivery Technology
  • 17.7. Aethlon Medical, Inc.
    • 17.7.1. Homopurifier
  • 17.8. Ambiotech
  • 17.9. AMS Biotechnology, Ltd. (AMSBIO)
    • 17.9.1. Products
  • 17.10. Anjarium Biosciences
    • 17.10.1. Anjarium's Hybridosome Platform
  • 17.11. Antibodies-Online GmbH
  • 17.12. Aposcience AG
    • 17.12.1. Wound Healing
    • 17.12.2. Myocardial Infarction
  • 17.13. Aruna Bio
    • 17.13.1. AB126
  • 17.14. Avalon GloboCare Corp.
    • 17.14.1. Avalon's Core Platforms
  • 17.15. Aviva Systems Biology
  • 17.16. Azymus Therapeutics
    • 17.16.1. AZ Platform
  • 17.17. Beckman Coulter Life Sciences
    • 17.17.1. Optima XPN
    • 17.17.2. Vi-CELL BLU - Cell Viability Analyzer
    • 17.17.3. SW 32 Swinging Bucket Rotor
    • 17.17.4. CytoFLEX - Flow Cytometer
  • 17.18. BioCat GmbH
    • 17.18.1. Exosome Purification Kits
  • 17.19. BioFluidica
  • 17.20. Biological Dynamics, Inc.
    • 17.20.1. Verita Isolation Platform
  • 17.21. Biorbyt, Ltd.
  • 17.22. BioRegenerative Sciences, Inc.
    • 17.22.1. SRM Technology
  • 17.23. Bio-Techne
    • 17.23.1. Products
  • 17.24. BioVision, Inc.
  • 17.25. BrainStorm Cell Therapeutics
    • 17.25.1. Exosomes for COVID-19
  • 17.26. BreStem Therapeutics, Inc.
  • 17.27. Capricor Therapeutics
    • 17.27.1. Exosome Program
  • 17.28. Carmine Therapeutics
  • 17.29. CD Bioparticles
    • 17.29.1. Exosome Services
  • 17.30. Cellarcus Biosciences, Inc.
    • 17.30.1. vFC Vesicle Analysis Assays
    • 17.30.2. vTag Antibodies
    • 17.30.3. Vesicles and Vesicle Standards
    • 17.30.4. Vesicle Analysis Services
    • 17.30.5. Measuring EV Size and Concentration
    • 17.30.6. Quantifying Vesicle Cargo
    • 17.30.7. Custom Analysis Services
  • 17.31. Cell Care Therapeutics
    • 17.31.1. CCT-101
  • 17.32. Cell Factory BVBA/Esperite NV
    • 17.32.1. Exosome Projects
  • 17.33. Cell Guidance Systems, Ltd.
    • 17.33.1. Exosomes from Cell Guidance
    • 17.33.2. Exo-Spin Exosome Purification
    • 17.33.3. Exosome Characterization
    • 17.33.4. ExoLISA Technology: Exosome Detection
    • 17.33.5. NTA Size Profiling Service
  • 17.34. Ciola
    • 17.34.1. Exosome Customization Technology
  • 17.35. CK-Exogene
  • 17.36. Clara Biotech
    • 17.36.1. ExoRelease
  • 17.37. Codiak Biosciences
    • 17.37.1. engEx Platform
    • 17.37.2. Pipeline Products
      • 17.37.2.1. exoSTING
      • 17.37.2.2. exolL-12
      • 17.37.2.3. exoASO-STAT6
  • 17.38. Coya Therapeutics, Inc.
  • 17.39. Craif, Inc.
    • 17.39.1. Nanowire Device
  • 17.40. Creative Bioarray
  • 17.41. CreativeBiostructure
  • 17.42. Creative Biolabs
    • 17.42.1. Products
    • 17.42.2. Services
  • 17.43. Creative Medical Technology Holdings
    • 17.43.1. AmnioStem Stroke Therapy
  • 17.44. Creative Proteomics
    • 17.44.1. Exosome Proteomics Services
  • 17.45. Curexsys GmbH
    • 17.45.1. Technology
  • 17.46. CUSABIO TECHNOLOGY LLC
    • 17.46.1. Exosome Isolation Kits
  • 17.47. Diadem Biotherapeutics
    • 17.47.1. Technology
  • 17.48. Direct Bio
    • 17.48.1. ExoFlo
    • 17.48.2. AmniWrap
  • 17.49. DLdevelop
  • 17.50. Entelexo Biotherapeutics
  • 17.51. EverZom
    • 17.51.1. Services
  • 17.52. Evomic Science LLC
    • 17.52.1. ExoEZ Exosome Isolation Kit
  • 17.53. Evora Biosciences SAS
  • 17.54. Evox Therapeutics, Ltd.
    • 17.54.1. Protein Therapeutics
    • 17.54.2. RNA Therapeutics
  • 17.55. ExBiome BV
    • 17.55.1. ExomiR Technology
  • 17.56. Exrkine Corp.
  • 17.57. ExoCan Healthcare Technologies, Pvt. Ltd.
    • 17.57.1. ExoEnrich Exosome Isolation Kit
    • 17.57.2. ExoEngineering
  • 17.58. ExoCoBio, Co., Ltd.
    • 17.58.1. Products
  • 17.59. Exogenus Therapeutics
  • 17.60. ExoPERT
    • 17.60.1. EXo-i
  • 17.61. ExoPharm
    • 17.61.1. LEAP Technology
    • 17.61.2. Cevaris & Plexaris
    • 17.61.3. Partnering Strategy
      • 17.61.3.1. Exosome Technologies
      • 17.61.3.2. Exosome Medicines
  • 17.62. ExosomeDx (biotechne)
    • 17.62.1. ExoDX Prostate Test
    • 17.62.2. Pharma Services
  • 17.63. ExosomePlus
  • 17.64. Exosome Sciences
    • 17.64.1. TauSome Biomarker
  • 17.65. Exosomics S.p.A
    • 17.65.1. ExoRef
    • 17.65.2. SeleCTEV-DNA Enrichment Kits
    • 17.65.3. SoRTEV-RNA Enrichment Kits
    • 17.65.4. evGAG
  • 17.66. ExoVectory
    • 17.66.1. EVY-101
  • 17.67. Florica Therapeutics
  • 17.68. GenWay Biotech, Inc.
  • 17.69. HansaBioMed Lifesiences, Ltd.
    • 17.69.1. Products
  • 17.70. ILIAS Biologics, Inc.
    • 17.70.1. EXPLOR
    • 17.70.2. Exo-Target
  • 17.71. Innocan Pharma
    • 17.71.1. CBD-Loaded Exosomes
  • 17.72. Innovex Therapeutics, S.L
    • 17.72.1. Research & Development
  • 17.73. INOVIQ, Ltd.
    • 17.73.1. EXO-NET (Research Use only)
  • 17.74. Invent Biotechnologies, Inc.
  • 17.75. Izon Science, Ltd.
    • 17.75.1. qEV Isolation
  • 17.76. Kimera Labs, Inc.
    • 17.76.1. XoGlo
    • 17.76.2. XoGlo Pro
    • 17.76.3. Equisome HC
  • 17.77. Leading Biology, Inc.
  • 17.78. LifeSpan Biosciences, Inc.
  • 17.79. Lonza Group, Ltd.
    • 17.79.1. Exosome Service
  • 17.80. Mantra Bio
    • 17.80.1. Partnering
  • 17.81. MDimune, Inc.
    • 17.81.1. BioDrone Technology
  • 17.82. Miltenyi Biotech B.V. and Co., KG
    • 17.82.1. qEV Exosome Isolation Kit
  • 17.83. miR Scientific
    • 17.83.1. Prostate Cancer Test
  • 17.84. Mursla, Ltd.
    • 17.84.1. ExoPheno
  • 17.85. MyBioSource, Inc.
  • 17.86. NanoSomics, Inc.
    • 17.86.1. Technology
  • 17.87. NanoView Biosciences
    • 17.87.1. ExoView R200
    • 17.87.2. ExoView R100
    • 17.87.3. ExoView Tetraspanin Kits
    • 17.87.4. ExoFlex Kits
  • 17.88. NeurExo Sciences
    • 17.88.1. Research & Development Programs
  • 17.89. NeuroDex, Inc.
  • 17.90. NurExone Biologic Ltd
  • 17.91. New England Peptide, Inc.
    • 17.91.1. ME- Kit for Exosome Isolation
  • 17.92. Norgen Biotek Corp.
    • 17.92.1. Services
  • 17.93. Novus Biologicals, LLC
    • 17.93.1. Exosome Research Tools
  • 17.94. nRix Dx, Inc.
  • 17.95. Oasis Diagnostics Corporation
    • 17.95.1. Pure.SAL
  • 17.96. OmniSpirant, Ltd.
    • 17.96.1. Technology
  • 17.97. Organicell
  • 17.98. OriGene Technologies, Inc.
  • 17.99. Paracrine Therapeutics, Pvt. Ltd.
  • 17.100. QIAGEN
    • 17.100.1. ExoEasy Maxi Kit
    • 17.100.2. miRCURY Exosome Kits
    • 17.100.3. miRCURY LNA miRNA Focus PCR Panels
  • 17.101. ReNeuron
    • 17.101.1. Exosome Platform
  • 17.102. RION
    • 17.102.1. Technology
  • 17.103. RoosterBio, Inc.
    • 17.103.1. RoosterCollect-EV
    • 17.103.2. RoosterCollect EV Pro
    • 17.103.3. RoosterCollect-EV-CC
    • 17.103.4. EV Boost
  • 17.104. Rosetta Exosome
  • 17.106. System Biosciences, LLC
    • 17.106.1. Exosome Research Products
    • 17.106.2. Exosome Research Services
  • 17.107. Tavec Pharma
    • 17.107.1. Technology
    • 17.107.2. Acquisition by Therillia
  • 17.108. Theoria Science, Inc.
    • 17.108.1. Technology: ExoScreen
  • 17.109. Thermo Fisher Scientific
    • 17.109.1. Exosome Products for Testing and Research
  • 17.110. TransGen Biotech, Co., Ltd.
  • 17.111. TriArm Therapeutics, Co., Ltd.
    • 17.111.1. Exosome Engineering Platform
  • 17.112. United Therapeutics Corp.
    • 17.112.1. Unexisome
  • 17.113. Versatope Therapeutics
    • 17.113.1. VT-105
  • 17.114. Vesigen Therapeutics, Inc.
    • 17.114.1. Technology
  • 17.115. VivaZome Therapeutics, Pvt. Ltd.
    • 17.115.1. VivaZome's Collaboration with ANU
    • 17.115.2. VivaZome's Collaboration with ReNerve
  • 17.116. Xollent Biotech
    • 17.116.1. Pipeline
  • 17.117. XOStem, Inc.
  • 17.118. YMAIR Genomics, LLC
    • 17.118.1. Urine Biomarker Isolation Method
    • 17.118.2. Ymatrix

INDEX OF FIGURES

  • FIGURE 2.1: Classification of Extracellular Vesicles
  • FIGURE 2.2: Exosome Formation
  • FIGURE 2.3: Exosome Uptake by Target Cells
  • FIGURE 2.4: Structure of an Exosome
  • FIGURE 2.5: Schematic of Membrane and Lumen Components of Exosomes
  • FIGURE 2.6: Classification of Exosomes according to Origin
  • FIGURE 2.7: Methods of Isolation for Natural Exosomes
  • FIGURE 2.8: Exosomes with Loaded Therapeutics in the Lumen and Surface Display
  • FIGURE 2.9: Schematic Representation of Therapeutic Applications of Exosomes
  • FIGURE 2.10: Sources of Exosomes for Research
  • FIGURE 3.1: Pre-Isolation Interior Modification Methods
  • FIGURE 3.2: Post-Isolation Interior Modification Methods
  • FIGURE 3.3: Surface Modification through the Parent Cells
  • FIGURE 3.4: Direct Surface Modification
  • FIGURE 5.1: Common Isolation Methods in Exosome Research
  • FIGURE 5.2: Exosome Labeling Methods in Exosome Biodistribution Analysis
  • FIGURE 5.3: Fluorescent Dyes used in Exosome Labeling
  • FIGURE 5.4: Common Methods to Remove Unlabelled Probes
  • FIGURE 5.5: Determination of Exosome Dose in Exosome Studies
  • FIGURE 5.6: Routes of Exosome Administration
  • FIGURE 5.7: Tested and Non-Tested Exosomes in Research
  • FIGURE 7.1: Number of PubMed Publications on Exosomes
  • FIGURE 7.2: Top Five Countries with Largest Number of Publications
  • FIGURE 7.3: Number of PubMed Publications on Exosome DNA as Diagnostics
  • FIGURE 7.4: Number of PubMed Publications on Exosome RNA as Diagnostics
  • FIGURE 7.5: PubMed Publications on Exosome Proteins as Diagnostics
  • FIGURE 7.6: PubMed Publications on Exosomes Derived from Stem Cells
  • FIGURE 7.7: PubMed Publications on Exosome-based Diagnostics
  • FIGURE 7.8: PubMed Publications on Exosome-based Therapeutics
  • FIGURE 7.9: PubMed Publications on Exosomes for Cancer Diagnosis
  • FIGURE 7.10: Publications on Exosome Diagnostics for Pregnancy Disorders
  • FIGURE 8.1: Patents/Applications Related to Exosome-Sources
  • FIGURE 8.2: Patents/Applications Related to Exosomes-Isolation/Preparation
  • FIGURE 8.3: Patents/Applications Related to Type of Cargo
  • FIGURE 8.4: Patents/Applications Related to Cargo Loading Methods
  • FIGURE 8.5: Patents/Applications Related to Therapy Area
  • FIGURE 8.6: Leading Assignees of Exosome Patents
  • FIGURE 9.1: Exosome Clinical Trials by Geography
  • FIGURE 10.1: Schematic Models of Continuous Exosome Manufacturing Approaches
  • FIGURE 10.2: Upstream Cell Line Production Methods
  • FIGURE 10.3: Downstream Exosome Purification Methods
  • FIGURE 11.1: Diagrammatic Representation of Differential Centrifugation
  • FIGURE 11.12: Diagrammatic Representation of Gradient Density Ultracentrifugation
  • FIGURE 11.3: Diagrammatic Representation of Ultrafiltration & Sequential Ultrafiltration
  • FIGURE 11.4: Diagrammatic Representation of Size-Exclusion Chromatography
  • FIGURE 11.5: Diagrammatic Representation of Polymer Precipitation
  • FIGURE 11.6: Diagrammatic Representation of Immunoaffinity Capture
  • FIGURE 11.7: Diagrammatic Representation of Microfluidics-based Techniques
  • FIGURE 11.8: Comparative Yield of Exosomes by Isolation Techniques
  • FIGURE 11.9: Relative Viability of Exosomes by Isolation Technique
  • FIGURE 12.1: Number of PubMed Published on Exosome Diagnostics, 2015-2021
  • FIGURE 13.1: Schematic Illustration of Key Points in Exosomes as Drug Delivery Systems
  • FIGURE 13.2: Sketch of a Naïve Exosome with Not-Fully Identified Functional Molecules
  • FIGURE 13.3: Passive Cargo Loading
  • FIGURE 13.4: Active Cargo Loading with Anchored Cargo
  • FIGURE 13.5: Active Cargo Loading with Free-Cargo
  • FIGURE 15.1: Diagnostic Applications of Exosomes
  • FIGURE 16.1: Market for Exosome Therapeutics and Diagnostics by Region, 2022-2030
  • FIGURE 16.2: Market for Exosome Research Products by Region, 2022-2030
  • FIGURE 16.3: Market Shares for Exosome Isolation Tools
  • FIGURE 16.4: Percent Utilization of Research Tools used on Captured Exosomes

INDEX OF TABLES

  • TABLE 2.1: Molecular Contents of Exosomes
  • TABLE 2.2: Common Protein Contents of Exosomes
  • TABLE 2.3: Common Lipid Contents of Exosomes
  • TABLE 2.4: Nucleic Acids Present in Cancer-Derived Exosomes
  • TABLE 2.5: Types of Therapeutic Cargo used in Exosome Modifications
  • TABLE 2.6: Differences between Exosome Therapy and Cell Therapy
  • TABLE 2.7: Comparative Studies using Exosomes from Different Sources
  • TABLE 3.1: Examples of Loaded and Displayed Molecules in Direct Exosome Engineering
  • TABLE 3.2: Advantages and Disadvantages of Exosome Preparation Methods
  • TABLE 3.3: Targeted Moieties used in Developing Targeted Designer Exosomes
  • TABLE 3.4: Exosome-Based Clinical Trials for Cancer Treatment and Diagnostics
  • TABLE 4.1: Select Preclinical Studies addressing Cardiovascular Diseases
  • TABLE 4.2: Select Preclinical Studies addressing Kidney Diseases
  • TABLE 4.3: Select Preclinical Studies addressing Liver Diseases
  • TABLE 4.4: Select Preclinical Studies addressing Wound Healing
  • TABLE 4.5: Select MSC Exosome-Based Clinical Trials for Regenerative Medicines
  • TABLE 5.1: Comparison of MISEV2018 and MFDS2018 Guidelines
  • TABLE 5.2: Comparison of Imaging Modalities used in Exosome Research
  • TABLE 5.3: Comparison of Exosome Labeling Methods
  • TABLE 6.1: Commercially Available Exosome Isolation Kits
  • TABLE 6.1: (CONTINUED)
  • TABLE 6.2: Exosome-associated RNA Isolation Kits
  • TABLE 6.3: Commercially Available Exosome Standards
  • TABLE 6.4: Commercially Available Immunoplates for Capturing Exosomes
  • TABLE 6.5: Commercially Available Immunobeads for Exosome Isolation
  • TABLE 6.6: Commercially Available Exosome Marker Antibodies
  • TABLE 8.1: Exosome Patent Assignees in 2021
  • TABLE 9.1: Recruitment Status for Exosome-based Clinical Trials
  • TABLE 9.2: Study Designs of Ongoing Exosome Clinical Trials
  • TABLE 9.3: Study Phases in Clinical Trials
  • TABLE 9.4: Phase III & Phase IV Studies in Clinical trials
  • TABLE 9.5: Funding Types for Exosome-based Studies
  • TABLE 9.6: Examples of Clinical Trials involving MSC-Derived Exosomes
  • TABLE 9.7: Examples of Clinical Trials involving Drug-Loaded Exosomes
  • TABLE 10.1: Companies Offering Exosome-Related Services
  • TABLE 10.1: (CONTINUED)
  • TABLE 11.1: Current Strategies for Exosome Isolation
  • TABLE 11.2: Active and Passive Methods of Microfluidics-based Platforms
  • TABLE 11.3: Features of Microfluidics-based Techniques
  • TABLE 11.4: Commercially Available Exosome Isolation Kits
  • TABLE 11.5: Summary of Different Exosome Isolation Techniques
  • TABLE 11.6: Approaches for Exosome Analysis of Gene and Protein Biomarkers
  • TABLE 11.7: Emerging Optical Technologies for Exosome Analysis
  • TABLE 11.8: Electrochemical and Electromechanical Approaches for Exosome Analysis
  • TABLE 12.1: Exosomal Cargo as Biomarkers for Disease Diagnosis
  • TABLE 12.1: (CONTINUED)
  • TABLE 12.2: Exosomal Proteins in Different Cancers
  • TABLE 12.3: Types of RNA as Biomarkers for Cancers
  • TABLE 12.4: Non-Coding RNAs in Exosomes as Biomarkers for Cancers
  • TABLE 12.5: Exosome Biomarkers for Cancer from other Body Fluids
  • TABLE 12.6: Target Exosome Molecules for Diagnosis in Pregnancy Disorders
  • TABLE12.6: (CONTINUED)
  • TABLE 12.7: Target Molecules of Exosomes for Diagnosis after Organ Transplantation
  • TABLE 12.8: Examples of Clinical Trials involving Exosome-based Diagnostics
  • TABLE 13.1: List of Commercial Companies Developing Exosomes Therapies
  • TABLE 13.2: Summary of Cargo Loading Methods
  • TABLE 13.3: Examples of Drugs Encapsulated in Exosomes
  • TABLE 13.4: Preclinical Studies involving Drug-Loaded Exosomes
  • TABLE 13.4: (CONTINUED)
  • TABLE 13.5: Phase III Clinical Trials involving Exosome Therapeutics
  • TABLE 14.1: The Potential of a New Approach to Cancer Vaccines in Animal Models
  • TABLE 14.2: Ongoing Clinical Trials of Exosome-Based Cancer Immunotherapy
  • TABLE 15.1: Companies Developing Exosome-Based Diagnostics
  • TABLE 15.2: Select Clinical Trials Evaluating Exosome Diagnostics
  • TABLE 15.3: List of Commercial Companies Developing Exosome Therapeutics
  • TABLE 15.4: Promising Exosome-Based Therapeutic Candidates
  • TABLE 15.5: A Short List of Diseases Addressed by Exosome Therapeutics
  • TABLE 15.6: Current Clinical Trials Update on Exosomal Vaccine Development
  • TABLE 15.7: Select Exosome-Based Clinical Trials
  • TABLE 15.7: (CONTINUED)
  • TABLE 15.8: The List of NIH Funding for Exosome-Based Research in 2022
  • TABLE 15.9: Deals and Fund Raising in Exosome Space, 2016-2022
  • TABLE 15.10: The Four Categories of Exosome Companies
  • TABLE 15.11: Exosome Technologies Developed by Commercial Companies
  • TABLE 16.1: Market for Exosome Therapeutics and Diagnostics by Region, 2022-2030
  • TABLE 16.2: Market for Exosome Research Products by Region, 2022-2030
  • TABLE 17.1: Aruna Bio's Product Pipeline
  • TABLE 17.2: BioCat's Exosome Tools: An Overview
  • TABLE 17.3: BreStem's Pipeline
  • TABLE 17.4: Capricor's Product Pipeline
  • TABLE 17.5: Cell Factory's Exosome Drug Candidates
  • TABLE 17.6: Codiak's engEx Therapeutic Pipeline
  • TABLE 17.7: Coya's Pipeline
  • TABLE 17.8: Curexsys' Products in Pipeline
  • TABLE 17.9: ILIAS Product Pipeline
  • TABLE 17.10: MDimune's Exosome-Based Products in Development
  • TABLE 17.11: NeurExo's Research & Development Programs
  • TABLE 17.12: Organicell's Product Pipeline
  • TABLE 17.13: Organicell's Pipeline - Compassionate Use IND
  • TABLE 17.14: RION's Pipeline of Products
  • TABLE 17.15: Xollent's Product Candidates
  • TABLE 17.16: All Known Exosome Companies Worldwide by Region and Activity
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제